Q&A: What Trump's First 100 Days Tell Us About America's Future
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Eli Lilly and GSK drive South Korea's drug licensing activity
China's growth as a drug licensing hub is well-treaded, but a surge in deals in South Korea means it is also becoming a go-to destination for big pharma companies, according to market analysis. According to the GlobalData deal database, the deal value for South Korean drug licensing agreements has so far reached $7.68bn this year, marking a 113% increase from 2024. The out-licensing of South Korean drugs to international firms surged by 180%, around a $5.1bn increase, from 2024 to so far in 2025. The momentum in out-licensing was largely fuelled by billion-dollar agreements among large pharma companies such as Eli Lilly and GSK. Eli Lilly outlaid $630m for OliX Pharmaceuticals' metabolic-associated steatohepatitis (MASH) candidate in February and agreed a separate $1.3bn deal for biotech Rznomics' RNA-based gene therapies in May. GSK meanwhile licensed ABL Bios' blood-brain barrier shuttle platform for $2.8bn in April. GlobalData senior business fundamentals analyst Ophelia Chan says: 'Once primarily recognised for generic drug production, South Korea is now transitioning into a global hub for novel innovative drug discovery and advanced drug technologies, bolstered by government support and increasing international investment. This transition positions the country as a strategic bridge between Western and Asian markets.' In January 2025, South Korea established the National Bio Committee to make the country one of five global leaders in the bio industry by 2035. Part of this mandate is to enhance the country's competitiveness in novel drug and advanced biopharmaceutical technology development. According to South Korea's Ministry of Science and IT, the committee plans to create a Won1tn ($695.7m) fund to promote private investment in the biopharmaceutical and vaccine industry. The initiative builds on ongoing reforms as the government aims to reduce drug development timelines and costs, GlobalData said. South Korea joins China as a fast-growing destination for promising pipeline drug candidates. The total deal value of US licensing of innovator drug candidates from Chinese biopharma companies has surged 280% since 2020. A bipartisan report in the US has called for at least $15bn of funding over the next five years to avoid being eclipsed by China in biotech advancement. The future of the US and European pharma industries' relationship with Chinese and South Korean companies will require sturdy trade relationships between the regions. This has been stretched this year with tariffs imposed by President Donald Trump as his administration looks to bolster domestic manufacturing in the US. While licensing deals do not equate to imported products, Trump has maintained that transferring technology to China poses a threat to national security. The controversial BIOSECURE Act, which would have blacklisted Chinese biotechs and manufacturers from accessing US funding and collaborating with US pharma companies, is still in regulatory limbo. Another announcement made by the US Food and Drug Administration (FDA) was for an immediate review of new clinical trials that involve sending American citizens' living cells to China and other hostile countries for genetic engineering and subsequent infusion back into US patients. This move may potentially impact deals that pharma and biotech's have in place with Chinese contract development and manufacturing organisations (CDMOs). "Eli Lilly and GSK drive South Korea's drug licensing activity" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Jim Cramer on Eli Lilly Stock: 'It Just Got Pole-Axed, Laid to Waste'
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer highlighted the reasons behind the stock's decline recently. He remarked: 'Last and least, I look at the drug stocks and I can't believe how awful they really are, with now Eli Lilly last joining the ugly fray with its less than impactful, less thought weight loss, the pill. The Street was hoping that Lilly would be able to replace its onerous GLP-1 injection with a simple pill that would produce an equal amount of weight loss. No such luck. The stock, it just got pole-axed, laid to waste.' Pixabay/Public Domain Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, obesity, cancer, autoimmune conditions, neurological disorders, and other diseases. The company's portfolio includes treatments across multiple therapeutic areas. In a July episode, Cramer mentioned the company and said: 'What I'm thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might be a short-term peak in the use of these drugs (GLP-1s). The Achilles heel of these drugs is that they're too effective. At some point, you lose enough weight, and you might think you can stop taking them… Whatever the case, if Eli Lilly is going to break out from this level, it needs breakthroughs in new areas, heart, brain, that it just doesn't have right now, or there has to be some new data that shows something else positive that the GLP-1 drugs can do. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
11 hours ago
- Bloomberg
Stock Movers: Bullish, CoreWeave, Cisco
On this edition of Stock Movers: - Bullish (BLSH) shares jumped 84% from the IPO price after the digital-asset exchange operator and owner of media outlet CoinDesk raised $1.1 billion in an initial public offering. Shares of the Cayman Islands-based company closed at $68 each on Wednesday in New York, nearly doubling its IPO price of $37 apiece. The offering was upsized earlier in the week to 30 million shares, and the price range was increased. The trading gives Bullish a market value of $9.9 billion based on the outstanding shares listed in its filing. The IPO ended more than 20 times oversubscribed, with about a third of orders receiving no shares at all, people familiar with the matter have said. - Walmart (WMT), Instacart (CART), and Kroger (KR) shares fell after Inc. announced plans to offer same-day grocery delivery in 2,300 cities by the end of the year. Customers will be able to order perishable items such as produce, dairy, meat, seafood and baked goods, alongside frozen foods and household items, the company said in a statement on Wednesday. Same-day grocery delivery is free for Amazon Prime subscribers on orders over $25 in most cities, it said. For non-members, the service carries a $12.99 fee, regardless of order size. - CoreWeave (CRWV) shares tumbled after the cloud-computing provider reported a wider quarterly loss and gave a disappointing earnings outlook, raising concerns about its rapid AI data center expansion pressuring profit margins. Third-quarter operating income will be $160 million to $190 million, the company said Tuesday, underwhelming investors looking to justify a near-quadrupling of its share price since its March debut. Costs are surging, and CoreWeave posted a loss of $131 million for the June quarter — more than 20 times bigger than the loss a year earlier. - Cisco Systems (CSCO) shares fell after the company gave a lukewarm forecast for the current fiscal year, disappointing investors who hoped for a boost from massive AI data center projects. Sales will be between $59 billion and $60 billion in the fiscal year that runs through July 2026, the company said in a statement Wednesday. At the midpoint, that's roughly in line with the average Wall Street estimate of $59.5 billion, according to data compiled by Bloomberg. Some analysts, though, we're looking for more than $61 billion.
